Will drug delivery through electricity have fewer side effects compared to oral drug in hand foot allergy?
Phase 2
Completed
- Conditions
- Health Condition 1: L309- Dermatitis, unspecified
- Registration Number
- CTRI/2019/08/020770
- Lead Sponsor
- SELF
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 99
Inclusion Criteria
Patients of age 18-60 years and consenting for the study.
Patients having palmoplantar hyperkeratotic eczema predominantly, having lesions of duration more than 8 weeks.
Exclusion Criteria
Non consenting patient.
Pregnant and lactating females
Patient with hematological, renal, hepatic disorder and having malignancy.
Patient those on pacemakers ,cardiac arrhythmias, metallic implanted devices in the area current flows or intrauterine metallic implantations .
Hypersensitivity to previous methotrexate.
Patient who are on other immunosuppresive agent.
Patient who had been on systemic or topical steroids for >2 months.
Patients of palmoplantar hyperkeratotic eczema with proven allergen will be excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Side effects both local and systemicTimepoint: 3 months
- Secondary Outcome Measures
Name Time Method Cure of the disease by HECSITimepoint: 3 MONTHS